Spyre Therapeutics, Inc.
SYRE
Classifica tra le azioni
#2336
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Prezzo delle azioni
$91.87
Capitalizzazione di mercato
$8.48B
Variazione (1 giorno)
8.44%
Variazione (1 anno)
291.10%
Paese
US
Scambia Spyre Therapeutics, Inc. (SYRE)
Categoria
Healthcare
Numero di azioni in circolazione per Spyre Therapeutics, Inc. (SYRE)
Numero di azioni in circolazione al June 2026: 84.73M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Spyre Therapeutics, Inc., il numero attuale di azioni in circolazione è 84.73M. Alla fine del December 2023, la società aveva 6.90M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Spyre Therapeutics, Inc. (SYRE) dal 2014 al 2026
Azioni in circolazione alla fine di ogni anno
| Anno | Azioni in circolazione | Cambia |
|---|---|---|
| 2026 (TTM) | 84.73M | 80.17% |
| 2024 | 47.03M | 581.85% |
| 2023 | 6.90M | 104.59% |
| 2022 | 3.37M | 28.19% |
| 2021 | 2.63M | 23.18% |
| 2020 | 2.13M | 67.05% |
| 2019 | 1.28M | 53.44% |
| 2018 | 832.90K | 37.64% |
| 2017 | 605.13K | 54.50% |
| 2016 | 391.67K | -14.33% |
| 2015 | 457.19K | -16.45% |
| 2014 | 547.19K | 0.00% |
Azioni in circolazione per aziende simili o concorrenti
| Azienda | Azioni in circolazione | Differenza | Il paese |
|---|---|---|---|
| 253.90M | 199.66% |
US
|
|
| 396.00M | 367.37% |
US
|
|
| 478.91M | 465.23% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -26.61% |
NL
|
